首页> 外文期刊>Antimicrobial agents and chemotherapy. >High-Level Resistance of Staphylococcus aureus to beta-Lactam Antibiotics Mediated by Penicillin-Binding Protein 4 (PBP4)
【24h】

High-Level Resistance of Staphylococcus aureus to beta-Lactam Antibiotics Mediated by Penicillin-Binding Protein 4 (PBP4)

机译:金黄色葡萄球菌对青霉素结合蛋白4(PBP4)介导的β-内酰胺抗生素的高水平抗性

获取原文
获取原文并翻译 | 示例
           

摘要

Penicillin-binding protein 4 (PBP4), a nonessential, low-molecular-weight penicillin-binding protein of Staphylococcus aureus, has been implicated in low-level resistance to beta-lactam antibiotics, although the mechanism is unknown. Mutations in PBP4 and its promoter were identified in a laboratory-generated mutant strain, CRB, which expresses high-level resistance to beta-lactams, including resistance to the new-generation cephalosporins active against methicillin-resistant strains of S. aureus. These mutations did not appreciably alter the beta-lactam antibiotic binding affinity of purified recombinant mutant PBP4 compared to that of wild-type PBP4. Compared to the susceptible parent strain, COLnex, the CRB strain produces a highly crosslinked cell wall peptidoglycan, indicative of increased transpeptidase activity. The pbp4 promoter mutation of CRB was associated with greatly increased amounts of PBP4 in membranes compared to those in the COLnex parent. Replacement of the native promoter of COLnex with the mutant promoter of CRB resulted in increased amounts of PBP4 in membranes and a highly cross-linked cell wall. PBP4 can be re-purposed to provide essential transpeptidase activity in vivo and confer high-level resistance to beta-lactam antibiotics, such as ceftobiprole and ceftaroline.
机译:青霉素结合蛋白4(PBP4),金黄色葡萄球菌的非必需低分子量的青霉素结合蛋白,虽然该机制是未知的,但对β-内酰胺抗生素的低水平抗性有影响。在实验室产生的突变菌株CRB中鉴定了PBP4及其启动子的突变,其表达对β-内酰胺的高水平抗性,包括对新一代头孢菌素的抗性对抗金黄色葡萄球菌的耐甲氧胞苷菌株。与野生型PBP4相比,这些突变未明显改变纯化的重组突变体PBP4的β-内酰胺抗生素结合亲和力。与敏感的亲本菌株(Colnex)相比,CRB菌株产生高度交联的细胞壁肽肽,其指示提高的转琥酯酶活性。与Colnex父母中的那些相比,CRB的PBP4启动子突变与膜中的PBP4大大增加。用CRB的突变促进剂替换COLNEX的天然启动子导致膜中的PBP4和高度交联的细胞壁增加。可以重新用PBP4以提供体内基本的转琥珀酶活性,并赋予β-内酰胺抗生素的高水平耐药性,例如头孢虫和头孢虫唑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号